HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.
Share
Why It Matters
An expert who follows Vir Biotechnology thinks the company is worth more money now. This means the expert believes Vir is doing well and has a good future ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.